KRONOS BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.739 USD | -0.81% |
|
-2.09% | -40.88% |
Financials (USD)
| Sales 2024 * | 6.74M | Sales 2025 * | 3.27M | Capitalization | 44.41M |
|---|---|---|---|---|---|
| Net income 2024 * | -93M | Net income 2025 * | -85M | EV / Sales 2024 * | -1.04 x |
| Net cash position 2024 * | 51.41M | Net Debt 2025 * | 28.09M | EV / Sales 2025 * | 22.2 x |
| P/E ratio 2024 * |
-0.46
x | P/E ratio 2025 * |
-0.49
x | Employees | 61 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.32% |
More Fundamentals
* Assessed data
More news
Latest transcript on Kronos Bio, Inc.
More recommendations
More press releases
| 1 day | -0.81% | ||
| 1 week | -2.09% | ||
| Current month | -6.46% | ||
| 1 month | -27.55% | ||
| 3 months | -30.28% | ||
| 6 months | -37.37% | ||
| Current year | -40.88% |
1 week
0.72
0.81
1 month
0.691.09
Current year
0.691.40
1 year
0.692.29
3 years
0.6928.42
5 years
0.6939.61
10 years
0.6939.61
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 68 | 18-03-31 | |
Joshua Kazam
FOU | Founder | 47 | 17-06-01 |
David Tanen
FOU | Founder | 52 | 17-06-01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Tanen
FOU | Founder | 52 | 17-06-01 |
Joshua Kazam
FOU | Founder | 47 | 17-06-01 |
Arie Belldegrun
FOU | Founder | 74 | 17-10-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-04 | 0.739 | -0.81% | 392,922 |
| 24-06-03 | 0.745 | -5.70% | 290,732 |
| 24-05-31 | 0.79 | +1.15% | 215,146 |
| 24-05-30 | 0.781 | -1.76% | 220,847 |
| 24-05-29 | 0.795 | +5.33% | 426,171 |
Delayed Quote Nasdaq, June 04, 2024 at 03:59 pm EDT
More quotes
Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics that target the deregulated transcription that causes cancer and other serious diseases. It is developing KB-0742, its internally discovered oral cyclin dependent kinase 9 (CDK9) inhibitor, for the treatment of MYC-amplified and others transcriptionally addicted solid tumors. It has initiated the Phase 2 portion of its Phase 1/2 clinical trial for KB-0742. It is also developing KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. Its scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases. Using its Small Molecule Microarray (SMM) platform or other approaches, it can generate and advance small molecule starting points into drug development candidates.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.739
USD
Average target price
4.125
USD
Spread / Average Target
+458.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -40.88% | 44.41M | |
| +46.19% | 55.7B | |
| -6.14% | 39.57B | |
| +39.19% | 39.91B | |
| -6.65% | 28.16B | |
| +12.33% | 26.3B | |
| -21.78% | 18.94B | |
| -0.35% | 12.12B | |
| +24.18% | 12.12B | |
| +28.38% | 12.17B |
- Stock Market
- Equities
- KRON Stock
